Literature DB >> 11889684

Chemotherapy-induced nausea and vomiting.

Catherine M Bender1, Roxanne W McDaniel, Kathleen Murphy-Ende, Mary Pickett, Cynthia N Rittenberg, Miriam P Rogers, Susan M Schneider, Rowena N Schwartz.   

Abstract

Nausea and vomiting (N&V) is among the most distressing side effects of chemotherapy, despite the development of more efficacious antiemetic agents. As many as 60% of patients who receive cancer chemotherapy experience some degree of N&V. However, the actual incidence is difficult to determine with accuracy because of the variety of drugs, doses, and health conditions of the patients who receive cancer treatments. This article examines the state of the science related to chemotherapy-induced nausea and vomiting and reviews both pharmacologic and behavioral strategies that have demonstrated efficacy in managing these distressing symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889684     DOI: 10.1188/02.CJON.94-102

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  11 in total

1.  Effect on Symptom Management Education Receiving Patients of Chemotherapy.

Authors:  Zümrüt Akgün Şahin; Seher Ergüney
Journal:  J Cancer Educ       Date:  2016-03       Impact factor: 2.037

2.  Preliminary evaluation of a predictive blood assay to identify patients at high risk of chemotherapy-induced nausea.

Authors:  Thomas Kutner; Emily Kunkel; Yue Wang; Kyle George; Erik L Zeger; Zonera A Ali; George C Prendergast; Paul B Gilman; U Margaretha Wallon
Journal:  Support Care Cancer       Date:  2016-10-12       Impact factor: 3.603

Review 3.  Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice.

Authors:  E S Antonarakis; R D W Hain
Journal:  Arch Dis Child       Date:  2004-09       Impact factor: 3.791

4.  Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting.

Authors:  Patrick Langford; Paul Chrisp
Journal:  Core Evid       Date:  2010-10-21

5.  Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.

Authors:  Agnes Glaus; Cornelia Knipping; Rudolf Morant; Christel Böhme; Burkhard Lebert; Frank Beldermann; Bernhard Glawogger; Paz Fernandez Ortega; André Hüsler; Robert Deuson
Journal:  Support Care Cancer       Date:  2004-10       Impact factor: 3.603

6.  Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.

Authors:  Katsunobu Oyama; Sachio Fushida; Masahide Kaji; Toshiya Takeda; Shinichi Kinami; Yasuo Hirono; Katsuhiro Yoshimoto; Kazuhisa Yabushita; Hisashi Hirosawa; Yuki Takai; Tatsuo Nakano; Hironobu Kimura; Toshiaki Yasui; Atsushi Tsuneda; Tomoya Tsukada; Jun Kinoshita; Takashi Fujimura; Tetsuo Ohta
Journal:  J Gastroenterol       Date:  2013-01-22       Impact factor: 7.527

Review 7.  Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.

Authors:  Toni M Dando; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Controlled release tablet formulation containing natural Δ(9)-tetrahydrocannabinol.

Authors:  Nagendra S Punyamurthula; Tushar Hingorani; Goutham Adelli; Waseem Gul; Mahmoud A ElSohly; Michael A Repka; Soumyajit Majumdar
Journal:  Drug Dev Ind Pharm       Date:  2015-12-07       Impact factor: 3.225

9.  Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.

Authors:  Paul Chrisp
Journal:  Core Evid       Date:  2007-03-31

10.  Helping patients discuss CINV management: development of a Patient Charter.

Authors:  Annie Young; Pascale Dielenseger; Paz Fernandez Ortega; Dolores Fernandez Perez; Philippa Jones; Elaine Lennan; Eileen O'Donovan; Sue Sharp; Alison Whiteford; Lilian Wiles
Journal:  Ecancermedicalscience       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.